Dermata Therapeutics, Inc. (DRMAW)San Diego, United States | NasdaqCM
0.02 USD
Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:01 p.m. EDT
DRMAW is currently trading at a very low price, with minimal volume and a negative trailing EPS. The recent price history shows no significant movement, and there are no dividend payouts. The company's fundamentals are weak, with negative returns on assets and equity, and the stock is not showing any momentum or positive indicators for short-term or long-term investment. It appears to be a speculative or high-risk asset with limited upside potential. |
| Attribute | Value |
|---|---|
| Beta | 0.50 |
| Website | https://www.dermatarx.com |
| Attribute | Value |
|---|---|
| Address1 | 3,525 Del Mar Heights Rd. |
| Address2 | Suite 332 |
| Ask | 0.0 |
| Ask Size | 0 |
| Beta | 0.503 |
| Bid | 0.0 |
| Bid Size | 0 |
| Book Value | 2.34 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.016 |
| Current Ratio | 4.794 |
| Custom Price Alert Confidence | HIGH |
| Day High | 0.016 |
| Day Low | 0.0111 |
| Display Name | Dermata Therapeutics |
| Ebitda Margins | 0.0 |
| Eps Trailing Twelve Months | -2.156 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Two Week High | 0.016 |
| Fifty Two Week High Change | 0.0 |
| Fifty Two Week High Change Percent | 0.0 |
| Fifty Two Week Low | 0.0111 |
| Fifty Two Week Low Change | 0.004900001 |
| Fifty Two Week Low Change Percent | 0.44144154 |
| Fifty Two Week Range | 0.0111 - 0.016 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,772,807,400,000 |
| Float Shares | 2,930,855 |
| Free Cashflow | -5,016,645 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 9 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Industry | |
| Industry Key | |
| Ipo Expected Date | 2,021-08-13 |
| Language | en-US |
| Long Business Summary | Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its lead product candidate is XYNGARI, which is in Phase 3 clinical studies for the treatment of moderate-to-severe acne, as well as completed Phase 1b proof of concept (POC) trial for mild-to-moderate psoriasis. The company is also developing DMT410 that has completed Phase 1b POC trials for the treatment of axillary hyperhidrosis and aesthetic skin conditions. It has a clinical trial collaboration agreement with Revance Therapeutics, Inc. to conduct a multi-center clinical trial to evaluate the topical application of XYNGARI with DAXXIFY, Revance's botulinum toxin type A. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. |
| Long Name | Dermata Therapeutics, Inc. |
| Market | us_market |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_283634456 |
| Net Income To Common | -7,558,557 |
| Open | 0.0229 |
| Operating Cashflow | -7,757,559 |
| Operating Margins | 0.0 |
| Phone | 858 800 2543 |
| Previous Close | 0.016 |
| Price Hint | 4 |
| Price To Book | 0.0068376074 |
| Profit Margins | 0.0 |
| Quick Ratio | 4.585 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 0.016 |
| Regular Market Day Low | 0.0111 |
| Regular Market Day Range | 0.0111 - 0.016 |
| Regular Market Open | 0.0229 |
| Regular Market Previous Close | 0.016 |
| Regular Market Price | 0.016 |
| Regular Market Time | 1,776,281,392 |
| Regular Market Volume | 1,700 |
| Return On Assets | -0.85253996 |
| Return On Equity | -1.94196 |
| Sand P52 Week Change | 0.38150132 |
| Sector | |
| Sector Key | |
| Short Name | Dermata Therapeutics, Inc. Warrant |
| Source Interval | 15 |
| State | CA |
| Symbol | DRMAW |
| Total Cash | 7,521,978 |
| Total Cash Per Share | 1.87 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.156 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Type Disp | Equity |
| Volume | 1,700 |
| Website | https://www.dermatarx.com |
| Zip | 92,130 |